# A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis

> **NCT02287922** · PHASE2 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 251 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** ALX-0061
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Tocilizumab

## Key facts

- **NCT ID:** NCT02287922
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2019-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02287922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02287922, "A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02287922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*